BioCryst Pharmaceuticals, Inc. (BCRX) Q1 2011 Earnings Results

Biocryst Pharmaceuticals Misses on EPS — Stock Down 3.87%

This earnings report indicates that Biocryst Pharmaceuticals is still facing significant challenges, particularly in managing expenses and achieving profitability. The stock's decline of 3.87% reflects investor disappointment with the EPS miss and the lack of revenue information. Without clear guidance on future performance, uncertainty remains high for investors.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.29	N/A	-43.56%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Management expressed concerns about the current financial performance and the path to profitability. They reiterated their commitment to long-term growth despite short-term setbacks.

Management highlighted ongoing challenges in achieving profitability.

They emphasized the need for continued investment in research and development.

Biocryst Pharmaceuticals Misses on EPS — Stock Down 3.87%

Key numbers

Management commentary

BioCryst Pharmaceuticals, Inc.

More earnings this week

Biocryst Pharmaceuticals Misses on EPS — Stock Down 3.87%

Key numbers

Management commentary